CAJ | 학술논문

目的：检测胶质瘤患者血浆中IGFBP-6的浓度，探讨其作为临床预测脑胶质瘤生存期标志物的可能性。方法：用酶联免疫吸附法（ELIISA）检测207例不同级别胶质瘤患者和36例正常对照者的血浆IGFBP6水平。采用方差分析（analysis of variance，ANOVA）比较胶质瘤患者与正常对照组及不同分级的胶质瘤患者的血浆IGFBP6水平，及对中位生存期的影像。结果：(1)低级别胶质瘤（Ⅱ级）患者血浆IGFBP-6平均水平(154.95±43.02ng/mL）较正常对照组(188.77±59.57ng/mL)明显降低(P<0.05)，亦明显低于高级别胶质瘤（Ⅲ，Ⅳ级）（183.14.95±71.43ng/mL）(P<0.05)，而高级别胶质瘤和正常对照之间无显著性差异。(2)Ⅲ级胶质瘤患者低血浆IGFBP6水平组生存期均值为711天（中位生存期，788天，95%CI，618-805）与高血浆IGFBP6水平组577天（中位生存期，607天，95%CI，510-644）相比有显著统计学差异(P<0.001)。结论：血浆IGFBP-6水平具有成为脑胶质瘤标记物的潜质，可能作为一个生物标记物来预测患者的生存期。
목적：검측효질류환자혈장중IGFBP-6적농도，탐토기작위림상예측뇌효질류생존기표지물적가능성。방법：용매련면역흡부법（ELIISA）검측207례불동급별효질류환자화36례정상대조자적혈장IGFBP6수평。채용방차분석（analysis of variance，ANOVA）비교효질류환자여정상대조조급불동분급적효질류환자적혈장IGFBP6수평，급대중위생존기적영상。결과：(1)저급별효질류（Ⅱ급）환자혈장IGFBP-6평균수평(154.95±43.02ng/mL）교정상대조조(188.77±59.57ng/mL)명현강저(P<0.05)，역명현저우고급별효질류（Ⅲ，Ⅳ급）（183.14.95±71.43ng/mL）(P<0.05)，이고급별효질류화정상대조지간무현저성차이。(2)Ⅲ급효질류환자저혈장IGFBP6수평조생존기균치위711천（중위생존기，788천，95%CI，618-805）여고혈장IGFBP6수평조577천（중위생존기，607천，95%CI，510-644）상비유현저통계학차이(P<0.001)。결론：혈장IGFBP-6수평구유성위뇌효질류표기물적잠질，가능작위일개생물표기물래예측환자적생존기。
Objective:To investigate the possibility of insulin-like growth factor binding protein 6(IGFBP6) as a po-tential prognosis predicator in the patients with cerebral glioma and the pathological grading value of its plasma concentra-tion. Methods:IGFBP-6 ELISA kit was used to measure the plasma IGFBP-6 concetrtion of 207 patients who had been newly diagnosed with cerebral glioma and 36 healthy volunteers. Grade Ⅲ glioma patients whose pathological tissue con-tained astrocytoma were compared. Results:(1)The preoperative plasma IGFBP-6 levels could significantly discriminate the surviwal of the two grade Ⅲ glioma subgroups ,with a mean survival time of 711days (the mean survival time, 788days, 95%CI,618-805) in low plasma IGFBP-6 level group versus mean survival time of 577days (the mean survival time, 607days,95%CI,510-644) in high plasma level group(P<0.001). (2)Plasma IGFBP-6 levels were significantly higher in pa-tients with high-grade glioma (183.14.95±71.43ng/mL)and healthy controls (188.77±59.57 ng/mL) than in patients with low-grade glioma (154.95±43.02ng/mL)(P<0.05);And no obvious difference of plasma IGFBP-6 levels was found between high-grade glioma patients and healthy controls. Conclusions: Plasma IGFBP-6 levels have the potential predictor value as a biomarker for pathological grading and follow-up of progression and survival in-grade Ⅲgliomas. Larger and broad-er population with an extended follow-up is needed to further validate these findings.